This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

End-payors oppose Takeda judgment motion in US Amitiza antitrust case

( October 7, 2025, 19:15 GMT | Official Statement) -- MLex Summary: End-payor plaintiffs opposed Takeda Pharmaceuticals' motion for summary judgment on their US antitrust claims over Amitiza, arguing Takeda asks for reconsideration of a federal court's previous orders without grappling with the high burden required for doing so. The federal court correctly ruled that several state law claims couldn't be dismissed under governing law, and the end-payors' claims are timely despite Takeda's recycled and meritless arguments, which it replicated in a previous judgment motion, the plaintiffs said in their opposition brief filed to the US District of Massachusetts.See attached document: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections